4 Analysts Have This To Say About Pediatrix Medical Group
Portfolio Pulse from Benzinga Insights
Analysts have varied opinions on Pediatrix Medical Group (NYSE:MD), with recent ratings showing a mix of bullish and indifferent sentiments. The average 12-month price target has increased by 21.37% to $10.62. Despite revenue growth, the company faces challenges with profitability and debt management.
September 26, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Pediatrix Medical Group (NYSE:MD) has received mixed analyst ratings, with a notable increase in the average price target to $10.62, reflecting a 21.37% rise. Despite this, the company faces challenges in profitability and debt management.
The mixed analyst ratings indicate uncertainty in the market's perception of Pediatrix Medical Group. The increase in the average price target suggests some optimism, but the company's financial challenges, such as low net margin and high debt-to-equity ratio, may offset positive sentiment, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100